BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dimopoulos MA, Jakubowiak AJ, McCarthy PL, Orlowski RZ, Attal M, Bladé J, Goldschmidt H, Weisel KC, Ramasamy K, Zweegman S, Spencer A, Huang JSY, Lu J, Sunami K, Iida S, Chng WJ, Holstein SA, Rocci A, Skacel T, Labotka R, Palumbo A, Anderson KC. Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma. Blood Cancer J 2020;10:17. [PMID: 32054831 DOI: 10.1038/s41408-020-0273-x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 35] [Article Influence: 11.5] [Reference Citation Analysis]
Number Citing Articles
1 Ailawadhi S, Ogbonnaya A, Murty S, Cherepanov D, Schroader BK, Romanus D, Farrelly E, Chari A. Duration of frontline therapy and impact on clinical outcomes in newly diagnosed multiple myeloma patients not receiving frontline stem cell transplant. Cancer Med 2022. [PMID: 36151787 DOI: 10.1002/cam4.5239] [Reference Citation Analysis]
2 Franz J, Myrus E, Sanchez L, Richter J. No needles needed: All-oral therapy options for relapsed & refractory multiple myeloma. Blood Reviews 2022. [DOI: 10.1016/j.blre.2022.100993] [Reference Citation Analysis]
3 Costa BA, Mouhieddine TH, Richter J. What's Old is New: The Past, Present and Future Role of Thalidomide in the Modern-Day Management of Multiple Myeloma. Target Oncol 2022. [PMID: 35771402 DOI: 10.1007/s11523-022-00897-8] [Reference Citation Analysis]
4 Gupta RK, Gupta A, Hillengass J, Holstein SA, Suman VJ, Taneja A, McCarthy PL. A review of the current status of lenalidomide maintenance therapy in multiple myeloma in 2022. Expert Rev Anticancer Ther 2022;:1-13. [PMID: 35503516 DOI: 10.1080/14737140.2022.2069564] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Xu GQ, Wang G, Bai XD, Wang XJ. Intramedullary nailing for pathological fractures of the proximal humerus caused by multiple myeloma: A case report and review of literature. World J Clin Cases 2022; 10(11): 3518-3526 [DOI: 10.12998/wjcc.v10.i11.3518] [Reference Citation Analysis]
6 Murakami N, Webber AB, Nair V. Transplant Onconephrology in Patients With Kidney Transplants. Adv Chronic Kidney Dis 2022;29:188-200.e1. [PMID: 35817526 DOI: 10.1053/j.ackd.2021.09.002] [Reference Citation Analysis]
7 Mack EKM, Hartmann S, Ross P, Wollmer E, Mann C, Neubauer A, Brendel C, Hoffmann J. Monitoring multiple myeloma in the peripheral blood based on cell-free DNA and circulating plasma cells. Ann Hematol 2022. [PMID: 35106639 DOI: 10.1007/s00277-022-04771-5] [Reference Citation Analysis]
8 Liu Y, Cheng P, Zhao W, Zhu L, Sui J, Dai Y, Lai Y. MiR-197-3p reduces bortezomib resistance in multiple myeloma by inhibiting IL-6 expression in a MEAF6-dependent manner. Leukemia Research 2022. [DOI: 10.1016/j.leukres.2022.106785] [Reference Citation Analysis]
9 Singh S, Sharma R, Singh J, Jain K, Paul D. Autologous stem cell transplantation for multiple myeloma in the novel agent era: Systematic review of Indian data and implications for resource constrained settings. J Can Res Ther 2022;0:0. [DOI: 10.4103/jcrt.jcrt_503_22] [Reference Citation Analysis]
10 Gorin NC. History and Development of Autologous Stem Cell Transplantation for Acute Myeloid Leukemia. Clin Hematol Int 2021;3:83-95. [PMID: 34820613 DOI: 10.2991/chi.k.210703.002] [Reference Citation Analysis]
11 Aksenova AY, Zhuk AS, Lada AG, Zotova IV, Stepchenkova EI, Kostroma II, Gritsaev SV, Pavlov YI. Genome Instability in Multiple Myeloma: Facts and Factors. Cancers (Basel) 2021;13:5949. [PMID: 34885058 DOI: 10.3390/cancers13235949] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
12 Papadimitriou MA, Papanota AM, Adamopoulos PG, Pilala KM, Liacos CI, Malandrakis P, Mavrianou-Koutsoukou N, Patseas D, Eleutherakis-Papaiakovou E, Gavriatopoulou M, Kastritis E, Avgeris M, Dimopoulos MA, Terpos E, Scorilas A. miRNA-seq and clinical evaluation in multiple myeloma: miR-181a overexpression predicts short-term disease progression and poor post-treatment outcome. Br J Cancer 2021. [PMID: 34718359 DOI: 10.1038/s41416-021-01602-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
13 Shen M, Zhang J, Tang R, Wang Y, Zhan X, Fan S, Huang Z, Zhong Y, Li X. Ixazomib-based maintenance therapy after bortezomib-based induction in patients with multiple myeloma not undergoing transplantation: A real-world study. Cancer Med 2021. [PMID: 34655168 DOI: 10.1002/cam4.4313] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
14 Efentakis P, Psarakou G, Varela A, Papanagnou ED, Chatzistefanou M, Nikolaou PE, Davos CH, Gavriatopoulou M, Trougakos IP, Dimopoulos MA, Andreadou I, Terpos E. Elucidating Carfilzomib's Induced Cardiotoxicity in an In Vivo Model of Aging: Prophylactic Potential of Metformin. Int J Mol Sci 2021;22:10956. [PMID: 34681615 DOI: 10.3390/ijms222010956] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
15 Moludi M, Rashidian A, Asghari MH, Nassireslami E, Yousefi Zoshk M, Hami Z, Paknejad B, Chamanara M. Curcumin induces potent cytotoxic effects on myeloma cells independent of caspase activation. Toxin Reviews. [DOI: 10.1080/15569543.2021.1892763] [Reference Citation Analysis]
16 Jones JR, Pawlyn C, Jackson GH. Safety of lenalidomide for maintenance treatment of patients with multiple myeloma following autologous stem cell transplantation. Expert Opin Drug Saf 2021;:1-9. [PMID: 34184970 DOI: 10.1080/14740338.2021.1945578] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
17 Spaan I, Timmerman LM, Kimman T, Slomp A, Cuenca M, van Nieuwenhuijzen N, Moesbergen LM, Minnema MC, Raymakers RA, Peperzak V. Direct P70S6K1 inhibition to replace dexamethasone in synergistic combination with MCL-1 inhibition in multiple myeloma. Blood Adv 2021;5:2593-607. [PMID: 34152396 DOI: 10.1182/bloodadvances.2020003624] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
18 Ozaki S, Handa H, Koiso H, Saitoh T, Sunami K, Ishida T, Suzuki K, Narita T, Iida S, Nakamura Y, Suzuki K, Nishimura N, Murakami H, Shimizu K. Propensity-score matched analysis of the efficacy of maintenance/continuous therapy in newly diagnosed patients with multiple myeloma: a multicenter retrospective collaborative study of the Japanese Society of Myeloma. J Cancer Res Clin Oncol 2021. [PMID: 34080068 DOI: 10.1007/s00432-021-03668-6] [Reference Citation Analysis]
19 Caillot M, Dakik H, Mazurier F, Sola B. Targeting Reactive Oxygen Species Metabolism to Induce Myeloma Cell Death. Cancers (Basel) 2021;13:2411. [PMID: 34067602 DOI: 10.3390/cancers13102411] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
20 Aliabadi F, Sohrabi B, Mostafavi E, Pazoki-Toroudi H, Webster TJ. Ubiquitin-proteasome system and the role of its inhibitors in cancer therapy. Open Biol 2021;11:200390. [PMID: 33906413 DOI: 10.1098/rsob.200390] [Cited by in Crossref: 1] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
21 Jasielec JK, Kubicki T, Raje N, Vij R, Reece D, Berdeja J, Derman BA, Rosenbaum CA, Richardson P, Gurbuxani S, Major S, Wolfe B, Stefka AT, Stephens L, Tinari KM, Hycner T, Rojek AE, Dytfeld D, Griffith KA, Zimmerman TM, Jakubowiak AJ. Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma. Blood 2020;136:2513-23. [PMID: 32735641 DOI: 10.1182/blood.2020007522] [Cited by in Crossref: 20] [Cited by in F6Publishing: 26] [Article Influence: 20.0] [Reference Citation Analysis]
22 Facon T, Venner CP, Bahlis NJ, Offner F, White DJ, Karlin L, Benboubker L, Rigaudeau S, Rodon P, Voog E, Yoon SS, Suzuki K, Shibayama H, Zhang X, Twumasi-Ankrah P, Yung G, Rifkin RM, Moreau P, Lonial S, Kumar SK, Richardson PG, Rajkumar SV. Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma. Blood 2021;137:3616-28. [PMID: 33763699 DOI: 10.1182/blood.2020008787] [Cited by in Crossref: 1] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis]
23 Cippitelli M, Stabile H, Kosta A, Petillo S, Gismondi A, Santoni A, Fionda C. Role of Aiolos and Ikaros in the Antitumor and Immunomodulatory Activity of IMiDs in Multiple Myeloma: Better to Lose Than to Find Them. Int J Mol Sci 2021;22:1103. [PMID: 33499314 DOI: 10.3390/ijms22031103] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
24 Laubach JP, Schjesvold F, Mariz M, Dimopoulos MA, Lech-Maranda E, Spicka I, Hungria VTM, Shelekhova T, Abdo A, Jacobasch L, Polprasert C, Hájek R, Illés Á, Wróbel T, Sureda A, Beksac M, Gonçalves IZ, Bladé J, Rajkumar SV, Chari A, Lonial S, Spencer A, Maison-Blanche P, Moreau P, San-Miguel JF, Richardson PG. Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study. Lancet Oncol 2021;22:142-54. [PMID: 33301738 DOI: 10.1016/S1470-2045(20)30680-X] [Cited by in Crossref: 9] [Cited by in F6Publishing: 22] [Article Influence: 4.5] [Reference Citation Analysis]
25 Stadler R, Scarisbrick JJ. Maintenance therapy in patients with mycosis fungoides or Sézary syndrome: A neglected topic. Eur J Cancer 2021;142:38-47. [PMID: 33217680 DOI: 10.1016/j.ejca.2020.10.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
26 Ding K, Yu H, Shao YY, Li LY, Wang CM, Song J, Li LJ, Fu R. Real-world Data on the Efficacy and Safety of Ixazomib-based Therapy in Multiple Myeloma: A Single-center Study in China. Cancer Manag Res 2020;12:8935-41. [PMID: 33061589 DOI: 10.2147/CMAR.S261887] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
27 Nagarajan C, Tan MS, Chen Y, Martinelli G, Cerchione C. Current and future perspectives of maintenance therapy in multiple myeloma. Panminerva Med 2020;62:225-33. [PMID: 32955180 DOI: 10.23736/S0031-0808.20.04117-8] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
28 Calafiore V, Giamporcaro S, Conticello C, Romano A, Parisi M, Giuffrida G, Tibullo D, Di Raimondo F, Signorelli SS. A Real-Life Survey of Venous Thromboembolic Events Occurring in Myeloma Patients Treated in Third Line with Second-Generation Novel Agents. J Clin Med 2020;9:E2876. [PMID: 32899553 DOI: 10.3390/jcm9092876] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
29 Storti P, Costa F, Marchica V, Burroughs-Garcia J, Dalla Palma B, Toscani D, Eufemiese RA, Giuliani N. Novel Approaches to Improve Myeloma Cell Killing by Monoclonal Antibodies. J Clin Med 2020;9:E2864. [PMID: 32899714 DOI: 10.3390/jcm9092864] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
30 Kumar SK, Jacobus SJ, Cohen AD, Weiss M, Callander N, Singh AK, Parker TL, Menter A, Yang X, Parsons B, Kumar P, Kapoor P, Rosenberg A, Zonder JA, Faber E Jr, Lonial S, Anderson KC, Richardson PG, Orlowski RZ, Wagner LI, Rajkumar SV. Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol 2020;21:1317-30. [PMID: 32866432 DOI: 10.1016/S1470-2045(20)30452-6] [Cited by in Crossref: 39] [Cited by in F6Publishing: 77] [Article Influence: 19.5] [Reference Citation Analysis]
31 Perkins J. Evolution and Innovation in Hematopoietic Cell Transplantation and Cellular Immunotherapy: Critical Updates in Therapeutics. Pharmacotherapy 2020;40:724-6. [PMID: 32808336 DOI: 10.1002/phar.2441] [Reference Citation Analysis]
32 Balitsky AK, Karkar A, McCurdy A, Rochwerg B, Mian HS. Maintenance therapy in transplant ineligible adults with newly-diagnosed multiple myeloma: A systematic review and meta-analysis. Eur J Haematol 2020;105:626-34. [PMID: 32710492 DOI: 10.1111/ejh.13496] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
33 Wong AH, Shin EM, Tergaonkar V, Chng WJ. Targeting NF-κB Signaling for Multiple Myeloma. Cancers (Basel) 2020;12:E2203. [PMID: 32781681 DOI: 10.3390/cancers12082203] [Cited by in Crossref: 7] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
34 Kostopoulos IV, Ntanasis-Stathopoulos I, Gavriatopoulou M, Tsitsilonis OE, Terpos E. Minimal Residual Disease in Multiple Myeloma: Current Landscape and Future Applications With Immunotherapeutic Approaches. Front Oncol 2020;10:860. [PMID: 32537439 DOI: 10.3389/fonc.2020.00860] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
35 Knauf W, Dingeldein G, Schlag R, Welslau M, Moehler T, Terzer T, Walter S, Habermehl C, Kunz C, Goldschmidt H, Raab MS; BPV trial group. First-line therapy with bendamustine/prednisone/bortezomib-A GMMG trial for non-transplant eligible symptomatic multiple myeloma patients. Eur J Haematol 2020;105:116-25. [PMID: 32155662 DOI: 10.1111/ejh.13409] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
36 Musto P, La Rocca F. Monoclonal antibodies in newly diagnosed and smoldering multiple myeloma: an updated review of current clinical evidence. Expert Rev Hematol 2020;13:501-17. [PMID: 32290723 DOI: 10.1080/17474086.2020.1753502] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]